Esophageal Cancer Treatment Guidelines

Introduction to Treatment Options

The European Society for Medical Oncology recommends that the treatment of esophageal cancer should be based on tumor stage, histological type, and patient fitness, with surgery as the standard treatment for early-stage disease (Tis-T2 N0), preoperative chemoradiotherapy for locally advanced disease (T3-T4 N0-1), and palliative approaches for metastatic disease 1, 2, 3

Diagnosis requires endoscopic biopsy with histology classified according to WHO criteria, distinguishing between squamous cell carcinoma (SCC), adenocarcinoma (AC), and small cell carcinoma 4, 1
Comprehensive staging should include clinical examination, blood counts, liver, pulmonary, and renal function tests 5
Endoscopy (including upper-aerodigestive tract endoscopy for tumors at/above tracheal bifurcation) is necessary for staging 1
CT scan of chest and abdomen is recommended for staging 1
Endoscopic ultrasound and PET-CT for surgical candidates to evaluate T and N categories 1
Laparoscopy for locally advanced (T3/T4) adenocarcinomas of the esophagogastric junction to rule out peritoneal metastases 1

Surgery is the treatment of choice for early cancer (Tis-T1a N0) 4, 5, 3
Endoscopic resection is a viable alternative for selected patients, with similar cure rates in specialized centers 1, 3

Surgery is the standard treatment for localized disease (T1-2 N0-1 M0) 1, 3
Transthoracic esophagectomy with two-field lymph node resection is recommended for intrathoracic SCC 6
At least six regional lymph nodes should be dissected and examined 5
For patients unable or unwilling to undergo surgery, combined chemoradiotherapy is superior to radiotherapy alone 3
For adenocarcinoma with suspected lymph node involvement (T1-2 N1-3 M0), preoperative therapy is recommended 1

Surgery alone is suboptimal for locally advanced disease (T3-T4 N0-1) since complete tumor resection is not possible in approximately 30% of pT3 and 50% of pT4 tumors 5, 6
Patients benefit from preoperative therapy, with preoperative chemoradiotherapy conferring a survival benefit according to meta-analyses 4, 5, 1
For adenocarcinoma, cisplatin/5-fluorouracil combined with radiotherapy followed by surgery is considered the best option 5
Patients with good tumor response to initial chemoradiotherapy may not require surgery and can be treated with definitive chemoradiotherapy 5, 6
Preoperative chemotherapy without radiation is an option for adenocarcinomas of the lower esophagus and esophagogastric junction 6

Treatment is palliative for metastatic disease (Stage IV) 4, 5
Chemotherapy may be given in selected patients 5
For dysphagia, esophageal stenting is cost-effective for restoring oral nutrition 5
A single dose of 12 Gy intra-cavitary brachytherapy may provide better long-term relief of dysphagia than stenting 5

Surgery is the standard treatment for operable patients with SCC, though long-term survival does not exceed 25% when regional lymph nodes are involved 4, 5
For patients unable or unwilling to undergo surgery, chemoradiotherapy is superior to radiotherapy alone 4, 5
Preoperative chemoradiotherapy improves rates of complete tumor resection, local tumor control, and survival 5

Surgery is routinely used for AC, with similar survival limitations as SCC 5
Cisplatin/5-fluorouracil combined with radiotherapy followed by surgery is considered the best option for locally advanced disease 5
Preoperative (and postoperative) chemotherapy is a treatment option for ACs of the lower esophagus and esophagogastric junction 6

Primary interdisciplinary planning of treatment is mandatory 3
Patient fitness significantly impacts treatment options - consider performance status, respiratory function, and comorbidities 1
Preoperative chemoradiotherapy may increase postoperative mortality, requiring careful patient selection 5
Regular follow-up after initial therapy has not been shown to influence outcomes; follow-up visits should focus on symptoms, nutrition, and psychosocial problems 5, 7